{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:08:51Z","timestamp":1792782531140,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"LABoratoires d\u2019EXcellence IGO","award":["ANR-11-LABX-0016-01"],"award-info":[{"award-number":["ANR-11-LABX-0016-01"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00262-020-02572-1","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T10:02:41Z","timestamp":1587204161000},"page":"1663-1672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial"],"prefix":"10.1007","volume":"69","author":[{"given":"Amir","family":"Khammari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Th\u00e9r\u00e8se","family":"Leccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Saiagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Pandolfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Chantal","family":"Knol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Qu\u00e9reux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chiffolettau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Labarri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dr\u00e9no","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,18]]},"reference":[{"issue":"8","key":"2572_CR1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14(8):463\u2013482","journal-title":"Nat Rev Clin Oncol"},{"key":"2572_CR2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CLEP.S99021","volume":"8","author":"FC Svedman","year":"2016","unstructured":"Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J (2016) Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe\u2014a systematic review of the literature. Clin Epidemiol 8:109\u2013122","journal-title":"Clin Epidemiol"},{"issue":"14","key":"2572_CR3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356","journal-title":"N Engl J Med"},{"issue":"23","key":"2572_CR4","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosenberg","year":"1985","unstructured":"Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313(23):1485\u20131492","journal-title":"N Engl J Med"},{"issue":"15","key":"2572_CR5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","volume":"86","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS et al (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86(15):1159\u20131166","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2572_CR6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00002371-200205000-00007","volume":"25","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL et al (2002) A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother 25(3):243\u2013251","journal-title":"J Immunother"},{"issue":"5594","key":"2572_CR7","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","volume":"298","author":"ME Dudley","year":"2002","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594):850\u2013854","journal-title":"Science"},{"issue":"24","key":"2572_CR8","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1158\/1078-0432.CCR-10-1297","volume":"16","author":"ME Dudley","year":"2010","unstructured":"Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC et al (2010) CD8+ enriched \"young\" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16(24):6122\u20136131","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2572_CR9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/PPO.0b013e31824d4465","volume":"18","author":"R Wu","year":"2012","unstructured":"Wu R, Forget MA, Chacon J, Bernatchez C, Haymaker C, Chen JQ et al (2012) Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18(2):160\u2013175","journal-title":"Cancer J"},{"issue":"15","key":"2572_CR10","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ et al (2016) long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen. Clin Cancer Res 22(15):3734\u20133745","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2572_CR11","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00262-002-0315-1","volume":"51","author":"B Dreno","year":"2002","unstructured":"Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S et al (2002) Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51(10):539\u2013546","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2572_CR12","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","volume":"63","author":"GC Prendergast","year":"2014","unstructured":"Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R et al (2014) Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother 63(7):721\u2013735","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"2572_CR13","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00262-007-0340-1","volume":"56","author":"A Khammari","year":"2007","unstructured":"Khammari A, Nguyen JM, Pandolfino MC, Quereux G, Brocard A, Bercegeay S et al (2007) Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 56(11):1853\u20131860","journal-title":"Cancer Immunol Immunother"},{"key":"2572_CR14","doi-asserted-by":"crossref","first-page":"186212","DOI":"10.1155\/2014\/186212","volume":"2014","author":"A Khammari","year":"2014","unstructured":"Khammari A, Knol AC, Nguyen JM, Bossard C, Denis MG, Pandolfino MC et al (2014) Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res 2014:186212","journal-title":"J Immunol Res"},{"issue":"1","key":"2572_CR15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.134.1.157","volume":"134","author":"MT Lotze","year":"1985","unstructured":"Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol 134(1):157\u201366","journal-title":"J Immunol"},{"issue":"4","key":"2572_CR16","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","volume":"135","author":"MT Lotze","year":"1985","unstructured":"Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CA et al (1985) In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 135(4):2865\u201375","journal-title":"J Immunol"},{"issue":"6","key":"2572_CR17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"2572_CR18","volume-title":"Evaluation of chemotherapeutic agents in cancer. MacLoad, editor","author":"D Karnofsky","year":"1949","unstructured":"Karnofsky D, Burchenal J (1949) Evaluation of chemotherapeutic agents in cancer. MacLoad, editor. Columbia University Press, New York"},{"issue":"8","key":"2572_CR19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","volume":"18","author":"EZ Keung","year":"2018","unstructured":"Keung EZ, Gershenwald JE (2018) The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther 18(8):775\u2013784","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"2572_CR20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00002371-199112000-00003","volume":"10","author":"F Jotereau","year":"1991","unstructured":"Jotereau F, Pandolfino MC, Boudart D, Diez E, Dreno B, Douillard JY et al (1991) High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10(6):405\u2013411","journal-title":"J Immunother"},{"issue":"3","key":"2572_CR21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/PL00006683","volume":"50","author":"MC Pandolfino","year":"2001","unstructured":"Pandolfino MC, Labarriere N, Tessier MH, Cassidanius A, Bercegeay S, Lemarre P et al (2001) High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement. Cancer Immunol Immunother 50(3):134\u2013140","journal-title":"Cancer Immunol Immunother"},{"key":"2572_CR22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0959-8049(95)00651-6","volume":"32a","author":"MH Tessier","year":"1996","unstructured":"Tessier MH, Pandolfino MC, Jotereau F, Boudart D, Litoux P, Dreno B (1996) Home therapy with autologous tumor-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma. Eur J Cancer Engl 32a:735\u2013736","journal-title":"Eur J Cancer Engl"},{"issue":"4","key":"2572_CR23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/eji.1830200417","volume":"20","author":"N Gervois","year":"1990","unstructured":"Gervois N, Heuze F, Diez E, Jotereau F (1990) Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol 20(4):825\u2013831","journal-title":"Eur J Immunol"},{"issue":"5","key":"2572_CR24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10616-010-9286-9","volume":"62","author":"MC Pandolfino","year":"2010","unstructured":"Pandolfino MC, Saiagh S, Knol AC, Dreno B (2010) Comparison of three culture media for the establishment of melanoma cell lines. Cytotechnology 62(5):403\u2013412","journal-title":"Cytotechnology"},{"issue":"8","key":"2572_CR25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.0906-6705.2004.00197.x","volume":"13","author":"N Chebassier","year":"2004","unstructured":"Chebassier N, El Houssein O, Viegas I, Dreno B (2004) In vitro induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 expression in keratinocytes by boron and manganese. Exp Dermatol 13(8):484\u2013490","journal-title":"Exp Dermatol"},{"issue":"25","key":"2572_CR26","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","volume":"99","author":"C Yee","year":"2002","unstructured":"Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E et al (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U.S.A 99(25):16168\u201316173","journal-title":"Proc Natl Acad Sci U.S.A"},{"issue":"10","key":"2572_CR27","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s00262-002-0313-3","volume":"51","author":"N Labarriere","year":"2002","unstructured":"Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dreno B et al (2002) Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 51(10):532\u2013538","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2572_CR28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00262-006-0204-0","volume":"56","author":"H Benlalam","year":"2007","unstructured":"Benlalam H, Vignard V, Khammari A, Bonnin A, Godet Y, Pandolfino MC et al (2007) Infusion of Melan-A\/Mart-1 specific tumor-infiltrating lymphocytes enhanced relapse-free survival of melanoma patients. Cancer Immunol Immunother 56(4):515\u2013526","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2572_CR29","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.4049\/jimmunol.175.7.4797","volume":"175","author":"V Vignard","year":"2005","unstructured":"Vignard V, Lemercier B, Lim A, Pandolfino MC, Guilloux Y, Khammari A et al (2005) Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol 175(7):4797\u20134805","journal-title":"J Immunol"},{"issue":"9","key":"2572_CR30","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.21873\/anticanres.13689","volume":"39","author":"D Zippel","year":"2019","unstructured":"Zippel D, Friedman-Eldar O, Rayman S, Hazzan D, Nissan A, Schtrechman G et al (2019) Tissue harvesting for adoptive tumor infiltrating lymphocyte therapy in metastatic melanoma. Anticancer Res 39(9):4995\u20135001","journal-title":"Anticancer Res"},{"key":"2572_CR31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMc1807505","volume":"379","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Robert C, Suciu S (2018) Adjuvant pembrolizumab in resected stage III melanoma. N Engl J Med U S 379:593\u2013595","journal-title":"N Engl J Med U S"},{"issue":"1","key":"2572_CR32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/pcmr.12315","volume":"28","author":"R Jewell","year":"2015","unstructured":"Jewell R, Elliott F, Laye J, Nsengimana J, Davies J, Walker C et al (2015) The clinicopathological and gene expression patterns associated with ulceration of primary melanoma. Pigment Cell Melanoma Res 28(1):94\u2013104","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"2572_CR33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","volume":"6","author":"MW Rohaan","year":"2018","unstructured":"Rohaan MW, van den Berg JH, Kvistborg P, Haanen JBAG (2018) Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J Immunother Cancer 6(1):102","journal-title":"J Immunother Cancer"},{"issue":"4","key":"2572_CR34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00403-015-1539-1","volume":"307","author":"X Zhang","year":"2015","unstructured":"Zhang X, Zhao Y, Ye Y, Li S, Qi S, Yang Y et al (2015) Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata. Arch Dermatol Res 307(4):319\u2013331","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"2572_CR35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ad.2012.06.018","volume":"105","author":"R Gonzalez","year":"2014","unstructured":"Gonzalez R, Torres-Lopez E (2014) Immunological basis of melanoma-associated vitiligo-like depigmentation. Actas Dermosifiliogr 105(2):122\u2013127","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"2572_CR36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","volume":"54","author":"K Boniface","year":"2018","unstructured":"Boniface K, Seneschal J, Picardo M, Taieb A (2018) Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy. Clin Rev Allergy Immunol 54(1):52\u201367","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02572-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T23:06:24Z","timestamp":1696028784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02572-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,18]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2572"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02572-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,18]]},"assertion":[{"value":"27 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial complied with all French (AgenceNationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9, ANSM,\u201d <i>Loi n\u00b0 2012\u2013300,<\/i> 5 Mars<i>2012<\/i> relative aux recherchesimpliquant la personnehumaine\u201d and all its amendments) and European requirements for the conduct of clinical trials (EuroepanMedicinec Agency, EMA, CPMP\/ICH\/377\/95, EMEA) and the principles of Good Clinical Practices, the 1964 Declaration of Helsinki, received approval for all study sites from the ethics committee of Nantes, France in December 2003 (CPP Ouest IV Nantes n\u00b0 553\/2005) and is registered at ClinicalTrials.gov under the Identifier: NCT00200577. All patients provided written informed consent prior to inclusion.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}